A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.
The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
This invention relates to Thypin, a new member of the human serpin polypeptide family, methods of making Thypin polypeptides and using these polypeptides to treat various medical disorders and to methods of screening for compounds that agonize or antagonize Thypin polypeptide activities.
This invention relates to Thypin, a new member of the human serpin polypeptide family, methods of making Thypin polypeptides and using these polypeptides to treat various medical disorders and to methods of screening for compounds that agonize or antagonize Thypin polypeptide activities.
Adel Youakim - Seattle WA, US Robert F. DuBose - Bellevue WA, US Steven R. Wiley - Seattle WA, US
Assignee:
Immunex Corporation - Thousand Oaks CA
International Classification:
C07K 1/00 G01N 33/53 A61K 38/00
US Classification:
530350, 435 71, 514 12
Abstract:
This invention relates to new members of the human Claudin polypeptide family, to methods of making such polypeptides, and to methods of using them to treat Claudin-associated conditions and to identify compounds that alter Claudin polypeptide activities.
Compositions And Methods Relating To Multimeric And Oligomeric Soluble Fragments Of The Tweak Receptor
The present invention provides methods and compositions relating to fusion proteins comprising multimeric soluble TWEAK receptor fragments and an oligomerization domain. Such fusion proteins are useful for antagonizing the TWEAK receptor and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and inflammatory conditions.
Kristine M. Kim - Mill Creek WA, US Steven R. Wiley - Seattle WA, US Randal R. Ketchem - Snohomish WA, US
Assignee:
Immunex Corporation - Thousand Oaks CA
International Classification:
C07K 16/00
US Classification:
5303881, 5303913
Abstract:
The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
Isbn (Books And Publications)
The Human Side Of High Performance: Empowering Yourself For The Future
David Kahn, Gianni Xeros, Casey Mock, Keisha Freeman, Travis Vandehey, Esther Mpyisi, Vincent Akinola, Ronald Johnson, Shannon Otoski, Bill Lonergan, Ricky Pace